# Safety and Immunogenicity of the rVSVΔG-ZEBOV-GP Ebola Virus Vaccine Candidate in Children Living in Lambaréné, Gabon

> **NCT05130398** · PHASE1,PHASE2 · COMPLETED · sponsor: **Centre de Recherche Médicale de Lambaréné** · enrollment: 120 (actual)

## Conditions studied

- Ebola Virus Disease

## Interventions

- **BIOLOGICAL:** rVSVΔG-ZEBOV-GP, V920
- **DIETARY_SUPPLEMENT:** Fibre and equilibrate breakfast and lunch
- **DIAGNOSTIC_TEST:** Active detection and treatment of pathogens
- **COMBINATION_PRODUCT:** Fibre and equilibrate breakfast and lunch plus Active detection and treatment of pathogens
- **BIOLOGICAL:** Chikenpox or Varicella vaccine (VARILRIX)
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT05130398
- **Lead sponsor:** Centre de Recherche Médicale de Lambaréné
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-04-09
- **Primary completion:** 2021-09-08
- **Final completion:** 2022-08-09
- **Target enrollment:** 120 (ACTUAL)
- **Last updated:** 2023-04-20

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05130398

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05130398, "Safety and Immunogenicity of the rVSVΔG-ZEBOV-GP Ebola Virus Vaccine Candidate in Children Living in Lambaréné, Gabon". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT05130398. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*